Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered to discuss cutting-edge developments, and the Image of the Year was a novel peptide-based PET tracer targeting PD-L1 in head and neck cancers.
Sessions covered the latest in tracer development, theranostics, total-body PET, and AI-powered imaging strategies. The apparent excitement and rapid learning between established researchers and rising talent underscore how quickly the field is evolving.
These innovations are more than academic—they inform the development of better diagnostic tools and smarter clinical trial designs. Axcellant is excited to apply insights from SNMMI 2025 to strengthen our imaging‑focused clinical research services, helping advance patient care through precision and innovation.
Axcellant, a specialist global contract research organization (CRO), has been appointed by Switzerland-based Santersus AG to support the execution of…
Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
Copyright @ 2026 Axcellant|Privacy Policy|Cookie Policy|